ArticleEuropean journal of nuclear medicine and molecular imaging2026
Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a highly sensitive modality for staging prostate cancer, a notable subset of patients presents with negative findings, leading to potential under-diagnosis. The incremental diagnostic value of multiparametric magnetic resonance imaging (mpMRI) in this specific cohort remains poorly defined. This study aimed to evaluate the added value of mpMRI in newly diagnosed prostate cancer patients with negative PSMA PET/CT results and to identify patient characteristics that predict this benefit.
methodsThis retrospective study included 200 patients with newly diagnosed, treatment-naïve prostate cancer who underwent both
resultsOf the 200 patients, 18 presented with negative
conclusionMultiparametric MRI provides significant added diagnostic value in detecting prostate cancer in newly diagnosed patients with negative
Indexed as
Identifiers
41111085What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.